Occurrence and fate of oseltamivir carboxylate (Tamiflu) and amantadine in sewage treatment plants

Chemosphere

Volumn 81, Issue 1, 2010, Pages 13-17

  Ghosh, Gopal Chandra ^a   Nakada, Norihide ^a   Yamashita, Naoyuki ^a   Tanaka, Hiroaki ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

Amantadine; Influenza; Oseltamivir (Tamiflu); Sewage treatment

Indexed keywords

ACTIVATED SLUDGE PROCESS; AMINES; ANOXIC WATER; ANTIVIRAL AGENTS; CARBOXYLATION; METABOLITES; OZONE; OZONIZATION; SEWAGE TREATMENT;

AMANTADINE; BIOLOGICAL NUTRIENT REMOVAL; CONVENTIONAL ACTIVATED SLUDGE TREATMENTS; INFLUENZA; INFLUENZA PANDEMICS; OSELTAMIVIR CARBOXYLATE; SECONDARY TREATMENT; TAMIFLU;

SEWAGE TREATMENT PLANTS;

AMANTADINE; OSELTAMIVIR; 4 ACETAMIDO 5 AMINO 3 (1 ETHYLPROPOXY) 1 CYCLOHEXENE 1 CARBOXYLIC ACID; ANTIVIRUS AGENT; OZONE; SEWAGE; WATER POLLUTANT;

ACTIVATED SLUDGE; ANTIMICROBIAL ACTIVITY; DRUG; EPIDEMIC; INFLUENZA; METABOLITE; POLLUTANT REMOVAL; RISK ASSESSMENT; SEWAGE TREATMENT;

ACTIVATED SLUDGE; AERATION; ANAEROBIC DIGESTION; ARTICLE; JAPAN; OZONATION; PANDEMIC INFLUENZA; SEWAGE EFFLUENT; SEWAGE TREATMENT PLANT; SLUDGE TREATMENT; ANALOGS AND DERIVATIVES; ANALYSIS; CHEMISTRY; ENVIRONMENTAL MONITORING; LIQUID CHROMATOGRAPHY; METABOLISM; PROCEDURES; SEWAGE; STATISTICS AND NUMERICAL DATA; TANDEM MASS SPECTROMETRY; WATER POLLUTANT; WATER POLLUTION;

AMANTADINE; ANTIVIRAL AGENTS; CHROMATOGRAPHY, LIQUID; ENVIRONMENTAL MONITORING; OSELTAMIVIR; OZONE; SEWAGE; TANDEM MASS SPECTROMETRY; WASTE DISPOSAL, FLUID; WATER POLLUTANTS, CHEMICAL; WATER POLLUTION, CHEMICAL;

EID: 77956060661     PISSN: 00456535     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.chemosphere.2010.07.023     Document Type: Article

References (23)

1. Accinelli C., Saccà M.L., Fick J., Mencarelli M., Lindberg R., Olsen B. Dissipation and removal of oseltamivir (Tamiflu) in different aquatic environments. Chemosphere 2010, 79:891-897.
2. Clara M., Kreuzinger N., Strenn B., Gans O., Kroiss H. The solids retention time - a suitable design parameter to evaluate the capacity of wastewater treatment plants to remove micropollutants. Water Res. 2005, 39:97-106.
3. Fick J., Lindberg R.H., Tysklind M., Haemig P.D., Waldenström J., Wallensten A., Olsen B. Antiviral oseltamivir is not removed or degraded in normal sewage water treatment: implications for development of resistance by influenza A virus. PLoS ONE 2007, 2(10):e986.
4. Gerdil C. The annual production cycle for infuenza vaccine. Vaccine 2003, 21:1776-1779.
5. Ghosh G.C., Nakada N., Yamashita N., Tanaka H. Oseltamivir carboxylate - the active metabolite of oseltamivir phosphate (Tamiflu), detected in sewage discharge and river water in Japan. Environ. Health Perspect. 2010, 118:103-107.
6. Gubareva L.V., Webster R.G., Hayden F.G. Comparison of the activities of Zanamivir, Oseltamivir, and RWJ-270201 against clinical isolates of influenza virus and neuraminidase inhibitor-resistant variants. Antimicrob. Agents Chemother. 2001, 45:3403-3408.
7. Internet Mental Health Database: (accessed 20.05.09). http://www.mentalhealth.com/drug/p30-s05.html.
8. Joss A., Keller E., Alder A.C., Göebel A., McArdell C.S., Ternes T., Siegrist H. Removal of pharmaceuticals and fragrances in biological wastewater treatment. Water Res. 2005, 39:3139-3152.
9. Kreuzinger N., Clara M., Strenn B., Kroiss H. Relevance of the sludge retention time (SRT) as design criteria for wastewater treatment plants for the removal of endocrine disruptors and pharmaceuticals from wastewater. Water Sci. Technol. 2004, 50(5):149-156.
10. Monto A.S., McKimm-Breschkin J., Macken C., Hampson A.W., Hay A., Klimov A., et al. Detection of influenza viruses resistant to neuraminidase inhibitors in global surveillance during the first 3 years of their use. Antimicrob. Agents Chemother. 2006, 50:2395-2402.
11. Olsen B., Munster V.J., Wallensten A., Waldenstrom J., Osterhaus A., Fouchier R.A.M. Global patterns of influenza A virus in wild birds. Science 2006, 312:384-388.
12. Prasse C., Schlüsener M.P., Schulz R., Ternes T. Antiviral drugs in wastewater and surface waters: a new pharmaceutical class of environmental relecance?. Environ. Sci. Technol. 2010, 44:1728-1735.
13. Saccà M.L., Accinelli C., Fick J., Lindberg R., Olsen B. Environmental fate of the antiviral drug Tamiflu in two aquatic cosystems. Chemosphere 2009, 75:28-33.
14. Singer A.C., Howard B.M., Johnson A.C., Knowles C.J., Jackman S., Accinelli C., Caracciolo A.B., Bernard I., Bird S., Boucard T., Boxall A., Brian J.V., Cartmell E., Chubb C., Churchley J., Costigan S., Crane M., Dempsey M.J., Dorrington B., Ellor B., Fick J., Holmes J., Hutchinson T., Karcher F., Kelleher S.L., Marsden P., Noone G., Nunn M.A., Oxford J., Rachwal T., Roberts N., Roberts M., Saccà M.L., Sanders M., Straub J.O., Terry A., Thomas D., Toovey S., Townsend R., Voulvoulis N., Watts C. Meeting report: Risk assessment of Tamiflu use under pandemic conditions. Environ. Health Perspect. 2008, 116:1563-1567.
15. Singer A.C., Nunn M.A., Gould E.A., Johnson A.C. Potential risks associated with the proposed widespread use of Tamiflu. Environ. Health Perspect. 2007, 115:102-106.
16. Soong G., Muir A., Gomez M.I., Waks J., Reddy B., Planet P., Singh P.K., Kaneko Y., Wolfgang M.C., Hsiao Y.S., Tong L., Prince A. Bacterial neuraminidase facilitates mucosal infection by participating in biofilm production. J. Clin. Invest. 2006, 116:2297-2305.
17. Söderström H., Järhult J.D., Olsen B., Lindberg R.H., Tanaka H., Fick J. Detection of the antiviral drug oseltamivir in aquatic environments. PLoS ONE 2009, 4(6):e6064.
18. Straub J.O. An environmental risk assessment for oseltamivir (Tamiflu®) for sewage works and surface waters under seasonal-influenza- and pandemic-use conditions Ecotoxicol. Environ. Saf. 2009, 72:1625-1634.
19. Suzuki H., Saito R., Masuda H., Oshitani H., Sato M., Sato I. Emergence of Amantadineresistance influenza A viruses: epidemiological study. J. Infect. Chemother. 2003, 9:195-200.
20. Martindale: The Complete Drug Reference 2007, Pharmaceutical Press, London, (Electronic Version). S.C. Sweetman (Ed.).
21. Virtual Computational Chemistry Laboratory (VCCLAB), ALOGPS Database. (accessed 20.05.09). http://www.vcclab.org/lab/alogps/start.html.
22. Organization New influenza A (H1N1) virus: global epidemiologic situation, June 2009. Wkly. Epidemiol. Rec. 2009, 84:249-257.
23. World Health Organization (WHO), 2010. Global Alert and Response: Pandemic (H1N1) 2009-update 83. (accessed 21.01.10). http://www.who.int/csr/don/2010_01_15/en/index.html.